Zürcher Nachrichten - Once-taboo ketamine booms for US at-home mental care

EUR -
AED 4.2804
AFN 77.00368
ALL 96.580114
AMD 443.844105
ANG 2.086359
AOA 1068.789777
ARS 1667.072313
AUD 1.75332
AWG 2.097951
AZN 1.972067
BAM 1.95641
BBD 2.346432
BDT 142.534443
BGN 1.956969
BHD 0.439237
BIF 3442.173288
BMD 1.165528
BND 1.509171
BOB 8.05051
BRL 6.337098
BSD 1.164963
BTN 104.746008
BWP 15.477826
BYN 3.34933
BYR 22844.356995
BZD 2.343021
CAD 1.610702
CDF 2601.459778
CHF 0.936391
CLF 0.027497
CLP 1078.694141
CNY 8.240402
CNH 8.237693
COP 4469.789828
CRC 569.077441
CUC 1.165528
CUP 30.886503
CVE 110.300339
CZK 24.202217
DJF 207.454686
DKK 7.468822
DOP 74.563249
DZD 151.128474
EGP 55.300711
ERN 17.482926
ETB 180.702444
FJD 2.634618
FKP 0.87379
GBP 0.873581
GEL 3.141131
GGP 0.87379
GHS 13.252075
GIP 0.87379
GMD 85.083348
GNF 10123.113015
GTQ 8.923897
GYD 243.734952
HKD 9.068103
HNL 30.683567
HRK 7.536076
HTG 152.507553
HUF 382.108583
IDR 19440.198145
ILS 3.771312
IMP 0.87379
INR 104.826468
IQD 1526.169321
IRR 49083.310339
ISK 149.000846
JEP 0.87379
JMD 186.468142
JOD 0.826379
JPY 180.641781
KES 150.704975
KGS 101.925779
KHR 4664.454402
KMF 491.852653
KPW 1048.974993
KRW 1710.424855
KWD 0.357782
KYD 0.970899
KZT 589.161176
LAK 25262.768695
LBP 104325.381679
LKR 359.340503
LRD 205.046574
LSL 19.744372
LTL 3.441503
LVL 0.705017
LYD 6.332975
MAD 10.760055
MDL 19.822096
MGA 5196.620335
MKD 61.65949
MMK 2447.140495
MNT 4134.564794
MOP 9.342073
MRU 46.457486
MUR 53.695494
MVR 17.951093
MWK 2020.129888
MXN 21.173224
MYR 4.786804
MZN 74.489031
NAD 19.744372
NGN 1688.908807
NIO 42.873184
NOK 11.769391
NPR 167.591256
NZD 2.01278
OMR 0.447119
PAB 1.165063
PEN 3.916021
PGK 4.94352
PHP 68.665964
PKR 326.607938
PLN 4.229528
PYG 8012.498341
QAR 4.246479
RON 5.092157
RSD 117.437121
RUB 89.449495
RWF 1695.028519
SAR 4.374346
SBD 9.592989
SCR 15.753845
SDG 701.063515
SEK 10.942261
SGD 1.509937
SHP 0.874448
SLE 27.624965
SLL 24440.545996
SOS 664.607228
SRD 45.023208
STD 24124.085063
STN 24.507536
SVC 10.194135
SYP 12887.05829
SZL 19.729152
THB 37.116255
TJS 10.68907
TMT 4.091005
TND 3.41751
TOP 2.806313
TRY 49.62585
TTD 7.898242
TWD 36.289912
TZS 2873.610463
UAH 48.90845
UGX 4121.267354
USD 1.165528
UYU 45.564794
UZS 13937.405549
VES 296.687514
VND 30729.156744
VUV 141.449819
WST 3.250206
XAF 656.161595
XAG 0.020144
XAU 0.000277
XCD 3.149899
XCG 2.099646
XDR 0.816054
XOF 656.161595
XPF 119.331742
YER 278.037051
ZAR 19.730882
ZMK 10491.15474
ZMW 26.934398
ZWL 375.299675
  • BCC

    -1.2100

    73.05

    -1.66%

  • NGG

    -0.5000

    75.41

    -0.66%

  • CMSD

    -0.0700

    23.25

    -0.3%

  • BTI

    -1.0300

    57.01

    -1.81%

  • SCS

    -0.0900

    16.14

    -0.56%

  • GSK

    -0.1600

    48.41

    -0.33%

  • AZN

    0.1500

    90.18

    +0.17%

  • BP

    -1.4000

    35.83

    -3.91%

  • RIO

    -0.6700

    73.06

    -0.92%

  • JRI

    0.0400

    13.79

    +0.29%

  • RBGPF

    0.0000

    78.35

    0%

  • CMSC

    -0.0500

    23.43

    -0.21%

  • BCE

    0.3300

    23.55

    +1.4%

  • RYCEF

    -0.0500

    14.62

    -0.34%

  • RELX

    -0.2200

    40.32

    -0.55%

  • VOD

    -0.1630

    12.47

    -1.31%

Once-taboo ketamine booms for US at-home mental care
Once-taboo ketamine booms for US at-home mental care

Once-taboo ketamine booms for US at-home mental care

Americans are paying to get a star of the psychedelic medicine movement –- ketamine -– shipped to them for at-home mental health treatments that are being called both a breakthrough and a gamble.

Text size:

A pandemic-spurred easing of prescription rules helped fuel a jump in telemedicine offerings of ketamine, an anesthetic that was once a taboo party drug but has become a buzzed-about tool against depression.

Yet long-term, large-scale studies of ketamine's medical impact are limited, leaving some experts concerned that an unregulated online boom could result in mishaps or a regulatory crackdown.

"This has to be rolled out slowly," said Boris Heifets, a Stanford University assistant professor of anesthesiology. "The risk is that we are scaling the fix but not the solution, which is a much more integrated approach to mental health."

Ketamine has been available in the United States since the 1970s as an anesthetic called a "dissociative" because of the hallucinogenic effects that have helped make it a rave culture drug.

It's legal for US doctors to prescribe, while some other psychedelics getting renewed attention for mental health uses like LSD or MDMA (also called ecstasy) are classified as having no medical utility and a high risk for abuse.

In this context, recent years have seen an uptick in clinics offering in-person intravenous ketamine treatments for depression, anxiety or chronic pain, though regulations and practices vary across American states.

- Ketamine 'babysitter' -

Then came the pandemic, which resulted in US authorities allowing doctors to remotely prescribe drugs like ketamine that previously required an in-person visit.

An increasing number of companies, some already doing in-clinic treatments, began offering to evaluate clients online and to send the drugs for home use to approved candidates.

Nue Life, which launched about a year ago, is one of those firms. Its CEO Juan Pablo Cappello estimated it has served over 3,000 ketamine patients so far.

"If you actually drill down on the sort of potentials for abuse here, you realize of course they exist, but we're creating a standard of care to make that quite unlikely," he told AFP.

For example, he noted clients are instructed to have an adult "babysitter" watch over them for the roughly 90 minutes the drug experience lasts, and he reasoned that people simply looking for ketamine could get it cheaper on the street.

Clients of the service, which costs $1,250 for a package providing six ketamine experiences, are encouraged but not obligated to couple it with therapy, Cappello said.

"The at-home telemedicine model, I would argue, is actually safer and more effective for patients," allowing more patients "to actually take advantage of these therapies," he added.

Heifets, the Stanford researcher, noted that making ketamine more available carries risks -- including the chances that authorities would tighten access if an at-home treatment resulted in some sort of tragedy.

- 'Change your life' -

US regulators in 2019 approved a type of ketamine specifically for adults with treatment-resistant depression, though with stringent rules like requiring patients to be monitored by a health care provider for at least two hours after their dose.

Americans have "a hair trigger for problem-solving through litigation," Heifets noted of the potential for lawsuits if things go wrong.

He was part of a team that analyzed the real-world effectiveness of intravenous ketamine therapy -- which can involve higher doses than the at-home services –- and reported most patients improved, though about eight percent said depressive symptoms worsened after treatment.

"We have very, very little evidence for our understanding of how effective ketamine is for depression at scale," he added.

Yet for people like 36-year-old New Yorker Philip Markle, who underwent an at-home treatment with a company called Mindbloom, ketamine is a profoundly useful tool.

Over his long battle with depression, the performer and comedian has tried medication, psychedelics like LSD, and talk therapy since the age of 12, but found something unique in ketamine.

Rather than the short-lived sense of change other treatments provided, ketamine imparted a sense of clarity and of helpful self-acceptance -– not the heavy effects he'd experienced with other psychedelics.

"It felt like if any drug could be administered through the mail, and you could do a psychedelic that could change your life, on your own, this would be the one," he told AFP.

L.Muratori--NZN